Home Newsfeeds Needham Reiterates Buy on Universal Display, Maintains $148 Price Target

Needham Reiterates Buy on Universal Display, Maintains $148 Price Target

Needham analyst James Ricchiuti reiterates Universal Display (NASDAQ:OLED) with a Buy and maintains $148 price target.

byBenzinga Newsdesk

February 24, 2023

1 minute read

Needham analyst James Ricchiuti reiterates Universal Display (NASDAQ:OLED) with a Buy and maintains $148 price target.

HC Wainwright & Co. Initiates Coverage On MoonLake with Buy Rating, Announces Price Target of $28

By Benzinga Newsdesk

July 21, 6:36 AM

HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on MoonLake (NASDAQ:MLTX) with a Buy rating and announces Price Target of $28.

MLTX

Sohu.Com Expects 4Q23 Brand Advertising Revenues Of $20M-$23M; Online Game Revenues Of $106M-$116M; Sees Non-GAAP Net Loss Of $10M-$20M

By Benzinga Newsdesk

November 13, 2:43 AM

For the fourth quarter of 2023, Sohu estimates: Brand advertising revenues to be between US$20 million and US$23 million; this implies an annual decrease of 20% to 31%, and a sequential

SOHU

FDA Pauses Gilead’s Investigational Magrolimab Study In Blood Cancer Patients

By Vandana Singh

August 21, 11:46 AM

FDA has placed a partial clinical hold on Gilead Sciences Inc (NASDAQ: GILD) initiation of new patients in U.S.

GILD

News

Hall of Fame Resort & Entertainment Company Announces 10-Year Mobile Sports Betting Agreement With Betr

By Bill Haddad

August 11, 8:02 AM

Betr becomes the Company's official mobile sports-betting partner and HOFV becomes a shareholder in Betr Betr is the first DTC micro-betting focused sports betting and media company for the next generation of

HOFV

Needham Reiterates Buy on Universal Display, Maintains $148 Price Target

Related Posts

HC Wainwright & Co. Initiates Coverage On MoonLake with Buy Rating, Announces Price Target of $28

Sohu.Com Expects 4Q23 Brand Advertising Revenues Of $20M-$23M; Online Game Revenues Of $106M-$116M; Sees Non-GAAP Net Loss Of $10M-$20M

FDA Pauses Gilead’s Investigational Magrolimab Study In Blood Cancer Patients

Hall of Fame Resort & Entertainment Company Announces 10-Year Mobile Sports Betting Agreement With Betr